A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc.
Genentech, Inc.
Shanghai Henlius Biotech
Bristol-Myers Squibb
BeOne Medicines
Merck Sharp & Dohme LLC
Neonc Technologies, Inc.
Daiichi Sankyo
Adaptimmune
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Innate Pharma
Inhibrx Biosciences, Inc
LG Chem
Massive Bio, Inc.
Incyte Corporation
Pfizer
Pfizer
Incyte Corporation
MacroGenics
Incyte Corporation
OncoC4, Inc.
Shattuck Labs, Inc.
Checkpoint Therapeutics, Inc.
Vincerx Pharma, Inc.
Molecular Templates, Inc.
Inhibrx Biosciences, Inc
Salubris Biotherapeutics Inc
RemeGen Co., Ltd.
Xencor, Inc.
NextCure, Inc.
Atreca, Inc.
Apexigen America, Inc.
Fate Therapeutics
Fate Therapeutics
Cantargia AB
Qilu Pharmaceutical Co., Ltd.
Fate Therapeutics
Bristol-Myers Squibb
Xencor, Inc.
Nektar Therapeutics
Advaxis, Inc.
Rubius Therapeutics
Xencor, Inc.
Incyte Corporation
PACT Pharma, Inc.
Genocea Biosciences, Inc.
Genocea Biosciences, Inc.
EMD Serono
Pfizer